Status:
COMPLETED
The Application of Remazolam in Gastroenteroscopy
Lead Sponsor:
Yangzhou University
Conditions:
Gastroenterology
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
OBJECTIVE: To study the safety, efficacy and clinical significance of remimazolam in the diagnosis and treatment of patients with daytime gastrointestinal endoscopy, calculate the optimal dose, and co...
Detailed Description
The study used up-and-down methods to calculate the ED50 and ED95. According to up-and-down method, group D1 and D2 were slowly injected 0.5μg/kg of remifentanil in advance, then 0.20mg/kg of remimazo...
Eligibility Criteria
Inclusion
- Age 18-65 years old; ASA classification I-II grade
Exclusion
- Asthma; allergic to the drugs involved and contraindicated; patients with severe respiratory system, cardiovascular system diseases and coagulation insufficiency of liver and kidney function; patients with severe neuropsychiatric system diseases
Key Trial Info
Start Date :
March 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2023
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT05357430
Start Date
March 1 2022
End Date
August 1 2023
Last Update
February 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Affiliated Hospital of Yangzhou University
Yangzhou, Jiangsu, China, 225000